Sanofi-aventis


GUILDFORD, England, December 17, 2010 - Sanofi-aventis and Oxford University have entered into an agreement to conduct multi-phase oncology clinical and translational research with INDOX, India's leading academic oncology network.

PARIS, November 8, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has sent a letter to Genzyme Corporation (Nasdaq: GENZ) requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.

PARIS, November 5, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation" (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research.

PARIS, October 26, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

PARIS, October 15, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
Older News
S M T W T F S
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
Copyright© 2010 The Gaea Times